Results 141 to 150 of about 3,103 (172)

Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. [PDF]

J Cyst Fibros
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS, PROMISE Study Group.   +14 more
europepmc   +1 more source

Cutaneous and Ocular Rosacea Associated with Elexacaftor, Tezacaftor and Ivacaftor, A Treatment for Cystic Fibrosis: A Case Report. [PDF]

J Pediatr Clin Pract
Piednoir A, Troussier F, Descamps M, Lagarce L, Martin L.   +4 more
europepmc   +1 more source

3D Automated Segmentation of Bronchial Abnormalities on Ultrashort Echo Time MRI: A Quantitative MR Outcome in Cystic Fibrosis. [PDF]

J Magn Reson Imaging
Bouzid AIH, Benlala I, de Senneville BD, Baldacci F, Macey J, Benhassen W, Su P, Bui S, Zysman M, Bustin A, Berger P, Dournes G.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Elexacaftor/ivacaftor/tezacaftor

Reactions Weekly
  +26 more sources

Elexacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2023
  +12 more sources

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis

Pediatric Pulmonology, 2022
OBJECTIVE: Elexacaftor/Tezacaftor/Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator with the potential to improve exercise capacity.
Adam J Causer, Jänis K Shute, Anthony I Shepherd   +2 more
exaly   +2 more sources

Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy

Journal of Cystic Fibrosis, 2022
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta) is the newest Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drug approved by the Food and Drug Administration.
David C Young, Brian Bourque, Martine H Antell   +2 more
exaly   +1 more source